Chemotherapy News and Research

Latest Chemotherapy News and Research

Physician performs research on cervical cancer

Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine.

24 Feb 2014

Blocking mechanisms for DNA repair may help to potentiate chemotherapy, says study

Chemotherapies are cancer treatments that work by inducing lesions in the DNA of tumour cells in order to inhibit their proliferation. However, the body naturally tries to repair these lesions, and thus reduces the efficacy of chemotherapy.

24 Feb 2014

Computerized safety checklist shows threefold drop in rates of serious type of hospital-acquired infection

A computerized safety checklist that automatically pulls information from patients' electronic medical records was associated with a threefold drop in rates of one serious type of hospital-acquired infection, according to a study by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford.

24 Feb 2014

Cell therapy: A powerful treatment for cancer patients

Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.

24 Feb 2014

New innovative technique can carry chemotherapy safely and release inside cancer cells

Researchers from the cancer nanotechnology and signal transduction and therapeutics programs of UCLA's Jonsson Comprehensive Cancer Center (JCCC) have developed an innovative technique that can carry chemotherapy safely and release it inside cancer cells when triggered by two-photon laser in the infrared red wave length.

24 Feb 2014

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality (VSQ) for up to one year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

HPV-positive oropharyngeal cancer patients show longer survival pattern than those related to smoking

People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive two years later if their cancer is caused by the human papillomavirus (HPV), new research led by a Johns Hopkins scientist suggests.

21 Feb 2014

Avastin can prolong the lives of women with advanced cervical cancer

New data showing cancer treatment Avastin (bevacizumab) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine.

21 Feb 2014

BDI Pharma joins with AstraZeneca to launch The MERREM Commitment Program

BDI Pharma today announced the launch of The MERREM Commitment Program with AstraZeneca, an assurance initiative offering customers security in product availability through contracted access to the original, branded MERREM I.V. from AstraZeneca.

20 Feb 2014

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

20 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Researchers propose new treatment to prevent mucositis in cancer patients

Experimental work pointing to a therapy for alleviating mucositis -- a common, severe side effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation - has been achieved by an international team of researchers from the US and Israel headed by scientists at the Hebrew University of Jerusalem.

20 Feb 2014

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

20 Feb 2014

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

20 Feb 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014

New biologic drug to prevent growth of ovarian cancer cells

Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.

20 Feb 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Physician performs research on cervical cancer

Blocking mechanisms for DNA repair may help to potentiate chemotherapy, says study

Computerized safety checklist shows threefold drop in rates of serious type of hospital-acquired infection

Cell therapy: A powerful treatment for cancer patients

New innovative technique can carry chemotherapy safely and release inside cancer cells

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

HPV-positive oropharyngeal cancer patients show longer survival pattern than those related to smoking

Avastin can prolong the lives of women with advanced cervical cancer

BDI Pharma joins with AstraZeneca to launch The MERREM Commitment Program

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Researchers propose new treatment to prevent mucositis in cancer patients

Lung cancer patients with Del19 mutation benefit most from afatinib

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

New biologic drug to prevent growth of ovarian cancer cells

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Researchers present new drug candidate that selectively kills cancer cells through starvation

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in